Development of an in vitro model to investigate joint ochronosis in alkaptonuria

Rheumatology

Volumn 50, Issue 2, 2011, Pages 271-277

  Tinti, Laura ^a,b   Taylor, Adam M ^b   Santucci, Annalisa ^a   Wlodarski, Brenda ^b   Wilson, Peter J ^b   Jarvis, Jonathan C ^b   Fraser, William D ^b   Davidson, John S ^c   Ranganath, Lakshminarayan R ^b   Gallagher, James A ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c University Hospitals NHS Trust   (United Kingdom)

Author keywords

Alkaptonuria; Arthropathy; Homogentisic acid; In vitro model; Ochronosis; Osteoarthritis

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; HOMOGENTISIC ACID; PIGMENT;

ALKAPTONURIA; ARTHROPATHY; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MICROSCOPY; OCHRONOSIS; OSTEOSARCOMA CELL; PIGMENTATION; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

ALKAPTONURIA; CELLS, CULTURED; HOMOGENTISIC ACID; HUMANS; JOINT DISEASES; MODELS, BIOLOGICAL; OCHRONOSIS;

EID: 78751699292     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq246     Document Type: Article

References (18)

1. Gaines JJ. The pathology of alkaptonuric ochronosis. Hum Pathol 1989;20:40-6.
2. La Du BN. Alkaptonuria. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease, Vol. 2. 8th edition. New York: McGraw-Hill, 2001:2109-23.
3. La Du BN, Zannoni VG, Laster L, Seegmiller JE. The nature of the defect in tyrosine metabolism in alkaptonuria. J Biol Chem 1958;230:251-60.
4. Fernandez-Canon JM, Granadino B, Beltran-Valero de Bernabe D et al. The molecular basis of alkaptonuria. Nat Genet 1996;14:19-24.
5. Zannoni VG, Malwista SE, La Du BN. Studies on ochronosis II. Studies on benzoquinoneacetic acid, a probable intermediate in the connective tissue pigmentation in alcaptonuria. Arthritis Rheum 1962;5:547-56.
6. O'Brien WM, La Du BN, Bunim JJ. Biochemical, pathologic and clinical aspects of alcaptonuria, ochronosis and ochronotic arthropathy: review of world literature (1584-1962). Am J Med 1963;34:813-38.
7. Helliwell TR, Gallagher JA, Ranganath LR. Alkaptonuria - a review of surgical and autopsy pathology. Histopathology 2008;53:503-12.
8. Taylor AM, Wilson PJ, Ingrams DR, Helliwell TR, Gallagher JA, Ranganath LR. Calculi and intracellular ochronosis in the submandibular tissues from a patient with alkaptonuria. J Clin Pathol 2010;63:186-8.
9. Keller JM, Macaulay W, Nercessian OA, Jaffe IA. New developments in ochronosis: review of the literature. Rheumatol Int 2005;25:81-5.
10. Kamoun P, Coude M, Forest M, Montagutelli X, Guenet JL. Ascorbic acid and alkaptonuria. Eur J Pediatr 1991;151:149.
11. Wolff JA, Barshop B, Nyhan WL et al. Effects of ascorbic acid in alkaptonuria: alterations in benzoquinone acetic acid and an ontogenic effect in infancy. Pediatr Res 1989; 26:140-4.
12. Anikster Y, Nyhan WL, Gahl WA. NTBC and alkaptonuria. Am J Hum Genet 1998;63:920-1.
13. Suwannarat P, O'Brien K, Perry MB et al. Use of nitisinone in patients with alkaptonuria. Metabol Clin Exp 2005;54: 719-7.
14. Phornphutkul C, Introne WJ, Perry MB et al. Natural history of alkaptonuria. New Engl J Med 2002;347: 2111-21.
15. Bancroft JD, Stevens A, eds., Theory and practice of histological techniques. 4th edition. London, UK: Churchill Livingstone, 1996:253.
16. Kirkpatrick CJ, Mohr W, Mutschler W. Experimental studies on the pathogenesis of ochronotic arthropathy. Virchows Arch [Cell Pathol] 1984; 47:347-60.
17. Angeles AP, Badger R, Gruber HE, Seegmiller JE. Chondrocyte growth inhibition induced by homogentisic acid and its partial prevention with ascorbic acid. J Rheumatol 1989;16:512-7.
18. Taylor AM, Wlodarski B, Prior IA et al. Ultrastructural examination of tissue in a patient with alkaptonuric arthropathy reveals a distinct pattern of binding of ochronotic pigment. Rheumatology 2010;49:1412-14.